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Abstract: Glutamate (Glu)-mediated excitotoxicity is a major cause of amyotrophic lateral sclerosis
(ALS) and our previous work highlighted that abnormal Glu release may represent a leading
mechanism for excessive synaptic Glu. We demonstrated that group I metabotropic Glu receptors
(mGluR1, mGluR5) produced abnormal Glu release in SOD1G93A mouse spinal cord at a late disease
stage (120 days). Here, we studied this phenomenon in pre-symptomatic (30 and 60 days) and
early-symptomatic (90 days) SOD1G93A mice. The mGluR1/5 agonist (S)-3,5-Dihydroxyphenylglycine
(3,5-DHPG) concentration dependently stimulated the release of [3H]d-Aspartate ([3H]d-Asp), which
was comparable in 30- and 60-day-old wild type mice and SOD1G93A mice. At variance, [3H]d-Asp
release was significantly augmented in 90-day-old SOD1G93A mice and both mGluR1 and mGluR5
were involved. The 3,5-DHPG-induced [3H]d-Asp release was exocytotic, being of vesicular origin
and mediated by intra-terminal Ca2+ release. mGluR1 and mGluR5 expression was increased in
Glu spinal cord axon terminals of 90-day-old SOD1G93A mice, but not in the whole axon terminal
population. Interestingly, mGluR1 and mGluR5 were significantly augmented in total spinal cord
tissue already at 60 days. Thus, function and expression of group I mGluRs are enhanced in the
early-symptomatic SOD1G93A mouse spinal cord, possibly participating in excessive Glu transmission
and supporting their implication in ALS. Please define all abbreviations the first time they appear in
the abstract, the main text, and the first figure or table caption.
Keywords: amyotrophic lateral sclerosis; SOD1G93A mice; spinal cord; metabotropic glutamate
receptor 1 (mGluR1); metabotropic glutamate receptor 5 (mGluR5); glutamate release;
mGluR1/mGluR5 expression; disease progression
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1. Introduction
Amyotrophic lateral sclerosis (ALS), originally described by Charcot in 1869, is a fatal progressive
neurodegenerative disease characterized by damage and death of upper and lower motor neurons
(MNs), leading to muscle wasting, weakness, and spasticity [1]. Although primary symptoms
of ALS are associated with motor dysfunction, up to 50% of patients develop cognitive and/or
behavioral impairment during the course of the disease and 13% present frontotemporal dementia [2–4].
The incidence of the disease is approximately 3 cases per 100,000 individuals per year, with a male:female
ratio of almost 2 [5]. To date, no drug is available to effectively counteract ALS progression. Only two
drugs have been approved for therapy: riluzole, which improves survival and quality of life only
modestly [6], and, very recently, edaravone, which shows some efficacy only in patients at the early
stage of the disease [7].
ALS can be sporadic (sALS), representing more than 90% of cases, or familial (fALS), which is
genetically transmissible and accounts for about 10% of cases. More than 30 genes involved in fALS have
been identified [8,9] and four of them, chromosome 9 open reading frame 72 (C9ORF72), superoxide
dismutase 1 (SOD1), TAR DNA-binding protein 43 (TARDBP), and mutations in fused in sarcoma
protein (FUS), are responsible for more than 70% of cases [10]. The pathogenesis of ALS is still unknown,
although clinical symptoms and disease progression are similar in sALS and fALS, indicating that
common mechanisms may be involved. Vulnerability of MNs has been ascribed to numerous causes,
including protein misfolding, mitochondrial dysfunction, oxidative damage, defective axonal transport,
glutamate-mediated excitotoxicity, insufficient growth factor signaling, and inflammation [11–14].
Moreover, the damage of MNs is enhanced by damage occurring in non-neuronal neighboring cells,
such as astrocytes and microglia, thus accelerating disease progression [15–17].
High levels of extracellular glutamate (Glu) have been detected in an elevated percentage of
sALS and fALS patients [18–20], suggesting that excitotoxicity plays an important role in motor
neuron degeneration. Impaired glutamate clearance, due to a reduced expression of the astrocyte
Glu transporters, has been proposed as the cause triggering excessive synaptic Glu [21–24]. However,
Glu transport defects do not seem to be the only origin of excessive extracellular Glu, since it has
been shown that the spontaneous release of Glu and that induced by depolarization [25], by group I
metabotropic Glu receptors (mGluRs) [26] or GABA and glycine hetero-transporter [27–29] activation,
is abnormal in the mouse model of human ALS expressing a high copy number of mutant human
superoxide dismutase 1 (SOD1) with a Gly93Ala substitution (SOD1G93A) [30].
In particular, we have demonstrated that group I mGluRs (including mGluR1 and mGluR5)
produced abnormal Glu release in the spinal cord of 120-day-old SOD1G93A mice, which represent
the late stage of the disease. Concentrations of the mGluR1/5 agonist (S)-3,5-Dihydroxyphenylglycine
(3,5-DHPG) > 0.3 µM stimulated the release of Glu to the same extent in the control and SOD1G93A
mice. At variance, concentrations ≤ 0.3 µM of 3,5-DHPG increased Glu release in SOD1G93A mice
only. Both mGluR1 and mGluR5 were involved, with mGluR5 being preferentially responsible for the
high potency effects of 3,5-DHPG. The release of Glu induced by 3,5-DHPG was exocytotic in nature
and it was sustained by intra-terminal Ca2+ release through inositol 1,4,5-triphosphate (IP3)-sensitive
Ca2+ channels.
Interestingly, the abnormal Glu release induced by hetero-transporter activation or axon terminal
membrane depolarization in SOD1G93A mice was also detectable before symptoms occur, as early as
30 days of life [31,32], suggesting that it can represent a cause rather than a consequence of disease
progression. This precociousness has not been explored in the case of Glu release induced by activation
of group I mGluRs. Therefore, in the present work, we investigated the modulation of Glu release
by mGluR1 and mGluR5 and the expression of these receptors in the SOD1G93A spinal cord at the
pre-symptomatic (30 and 60 days) and early-symptomatic (90 days) stages of the disease.
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2. Results
2.1. Effects of 3,5-DHPG on [3H]d-Aspartate Release during Disease Progression
Here, we studied the release of [3H]d-Aspartate ([3H]d-Asp) induced by the mixed mGluR1/5
agonist 3,5-DHPG [33] from 30-, 60-, and 90-day-old WT and SOD1G93A mouse synaptosomes in
superfusion. The amount of tritium loaded into the preparation per mg of protein did not vary under
the different conditions tested. The exposure of spinal cord synaptosomes to 3,5-DHPG (0.03–30 µM)
concentrations dependently stimulated the release of [3H]d-Asp in wild type mice (WT) and SOD1G93A
mice at the three disease stages (Figure 1A–C). No differences were observed between WT and SOD1G93A
mice at 30 (Figure 1A; F(1,3,3,33) = 0.189) or 60 (Figure 1B; F(1,3,3,17) = 0.0423) days of age. Also, the exposure
of 90-day-old spinal cord synaptosomes to increasing concentrations of 3,5-DHPG generated similar
effects in WT and SOD1G93A mice, except at 0.3 µM 3,5-DHPG, which produced a significant increase of
the release in SOD1G93A with respect to WT mice (Figure 1C; p < 0.05; F(1,3,3,48) = 1.502).
Figure 1. Release of [3H]d-Aspartate ([3H]d-Asp) in spinal cord synaptosomes purified from wild
type mice (WT) and SOD1G93A mice. The effect of (S)-3,5-dihydroxyphenylglycine (3,5-DHPG) on the
spontaneous release of [3H]d-Asp was measured in spinal cord synaptosomes prepared from SOD1G93A
mice at different stages of the disease: (A) 30 days of life, (B) 60 days of life, and (C) 90 days of life,
corresponding to pre-symptomatic (30 and 60 days) and early-symptomatic (90 days) phases of the
disease. Age-matched WT animals were used as controls. Synaptosomes were loaded with [3H]d-Asp,
in order to label the intra-terminal releasing pools of Glu, and exposed in superfusion to increasing
concentrations (0.03, 0.3, 3, and 30 µM) of 3,5-DHPG. Labelling by [3H]d-Asp did not differ significantly
between WT and SOD1G93A mice when normalized for synaptosomal protein. Superfusion samples
collected were counted for radioactivity. Results are expressed as the percent increase respect to the
basal control release. The data reported are the means ± SEM of five independent experiments (five WT
and five SOD1G93A mice) run in triplicate (three superfusion chambers for each experimental condition).
No significance was detected in 30- and 60-day-old mice, while a significant difference was found
in 90-day-old SOD1G93A mice versus WT mice. * p < 0.001 vs. WT (two-way ANOVA followed by
Bonferroni’s post-hoc test).
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These data show that the 3,5-DHPG-induced [3H]d-Asp release is abnormally increased in
90-day-old SOD1G93A mice, but not at earlier disease stages.
2.2. Mechanisms Underlying the Modulation of [3H]d-Aspartate Release by 3,5-DHPG in 90-Day-Old Mice
In order to define the mGlu receptor subtype involved in the abnormal [3H]d-Asp release induced
by 0.3 µM 3,5-DHPG in 90-day-old SOD1G93A mice, we tested the competitive mGluR1 antagonist
(S)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic acid (LY367385) [34] and the non-competitive
mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) [35] on the 3,5-DHPG-releasing effect.
The 0.3 µM 3,5-DHPG-induced [3H]d-Asp release was strongly reduced by both antagonists, used
at the concentration of 1 µM (Figure 2A; p < 0.05; F(4,9) = 8.422), thus indicating that both mGluR1 and
mGluR5 contribute to the abnormal release of [3H]d-Asp observed at this disease stage.
Since mGluR1 and mGluR5 induce Ca2+ mobilization form intracellular stores [36], we studied
the cytosolic calcium concentration ([Ca2+]C) in spinal cord synaptosomes from 90-day-old WT and
SOD1G93A mice, under basal conditions and following exposure to 3,5-DHPG by labelling with the
fura-2-acetoxymethyl ester (FURA 2-AM) fluorescent dye. As shown in Figure 2B, the [Ca2+]C in
the absence of 3,5-DHPG was significantly more elevated in synaptosomes from SOD1G93A with
respect to WT mice (p < 0.001; F(1,3,3,30) = 11.154). Exposure to 0.3, 3, or 30 µM 3,5-DHPG induced
a concentration-dependent increase of [Ca2+]C in both mouse strains (p < 0.001; F(1,3,3,30) = 11.154).
3,5-DHPG produced a further [Ca2+]C increase, leading to a total [Ca2+]C that was significantly greater
in SOD1G93A mice than that measured in WT mice (p < 0.001; F(1,3,3,30) = 11.154).
In order to verify the origin of Ca2+ producing the increase of [Ca2+]C, we analyzed the release of
[3H]d-Asp in spinal cord synaptosomes from 90-day-old SOD1G93A mice exposed to 0.3 µM 3,5-DHPG
in the absence of external Ca2+, as well as in Ca2+-containing standard medium but in synaptosomes
incubated in the presence of 100 µM 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic
acid tetrakis acetoxymethyl ester (BAPTA-AM) prior to release experiments, to block
intracellular Ca2+ [37], or exposed in superfusion to the phospholipase C inhibitor
1-[6-[((17β)-3-methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,5-dione (U73122)
(1 µM) [38] or to the IP3 receptor blocker 2-aminoethoxydiphenyl borate (2-APB) (10 µM) [39].
Figure 2C shows that omission of Ca2+ in the superfusion medium did not reduce the release of
[3H]d-Asp evoked by 3,5-DHPG.
On the contrary, the effect of 3,5-DHPG on [3H]d-Asp release was abolished by BAPTA-AM in
the presence of external Ca2+, by 2-APB (p < 0.001; F(5,28) = 567.116), or by U73122 (p < 0.001; F(5,28) =
567.116). Figure 2C also shows that the effect of 0.3 µM 3,5-DHPG was occluded by pre-incubation
of synaptosomes with 0.1 µM bafilomycin A1, a drug that depletes the vesicular neurotransmitter
content [40] (p < 0.001; F(5,28) = 567.116).
These data demonstrate that [Ca2+]C is abnormally augmented in spinal cord synaptosomes
from 90-day-old SOD1G93A mice because of its release from endoplasmic reticulum stores through IP3
receptor channels and that the increase of the release of [3H]d-Asp by 0.3 µM 3,5-DHPG is exocytotic
in nature.
Int. J. Mol. Sci. 2019, 20, 4552 5 of 19
Figure 2. Mechanisms underlying the 3,5-DHPG-evoked [3H]d-Asp release in spinal cord synaptosomes
from 90-day-old WT and SOD1G93A mice. (A) The effects of mGluR1 and mGluR5 selective antagonists
were tested on the 0.3 µM 3,5-DHPG-evoked [3H]d-Asp release. Spinal cord synaptosomes were
exposed in superfusion to 1 µM LY367385 or MPEP, 8 min before and concomitantly with 0.3 µM
3,5-DHPG. See the legend of Figure 1 for other technical details. The data reported are the means ± SEM
of five independent experiments (five WT and five SOD1G93A mice) run in triplicate (three superfusion
chambers for each experimental condition). * p < 0.05 vs. 3,5-DHPG (one-way ANOVA followed
by Bonferroni’s post-hoc test). (B) Resting and 3,5-DHPG-evoked [Ca2+]C were measured in
spinal cord synaptosomes purified from 90-day-old SOD1G93A and age-matched WT control mice.
Synaptosomes were labelled with fura-2-acetoxymethyl ester (fura 2-AM) and exposed to standard
medium or to 0.3, 3, and 30 µM 3,5-DHPG. [Ca2+]C was determined fluorometrically as described
in the Methods section. Data are means ± SEM of three independent experiments (three WT and
three SOD1G93A mice) run in triplicate (three experimental replicates). * p < 0.001 vs. WT mice
(two-way ANOVA followed by Bonferroni’s post-hoc test). (C) The effects of external calcium absence
(Ca-free medium), cytosolic calcium chelation by 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic
acid tetrakis acetoxymethyl ester (BAPTA-AM) (100 µM), phospholipase C inhibition by
1-[6-[((17β)-3-methoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,5-dione (U73122) (1 µM),
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IP3 receptor blockade by 2-aminoethoxydiphenyl borate (2-APB) (10 µM), or vesicular neurotransmitter
deprivation by bafilomycin A1 (0.1 µM) were tested on the 0.3 µM 3,5-DHPG-evoked [3H]d-Asp release
in spinal cord synaptosomes purified from 90-day-old SOD1G93A and age-matched WT mice. Spinal
cord synaptosomes were labelled with [3H]d-Asp and exposed in superfusion to 0.3 µM 3,5-DHPG and
to the above mentioned experimental conditions, as described under the Methods section. The presence
of BAPTA-AM or bafilomycin A1 did not significantly affect synaptosomal labelling by [3H]d-Asp.
Results are expressed as the percent increase with respect to the basal control release. The data reported
are the means ± SEM of four independent experiments (four WT and four SOD1G93A mice) run in
triplicate (three superfusion chambers for each experimental condition). * p < 0.001 vs. the effect of
3,5-DHPG (one-way ANOVA followed by Dunnett’s post-hoc test).
2.3. Expression of mGluR1 and mGluR5 in Spinal Cord Glutamatergic Synaptosomes during
Disease Progression
In order to evaluate possible changes in the expression of mGluR1 and mGluR5 during disease
progression, we carried out western blot (WB) experiments using protein extracts of spinal cord
synaptosomes from 30-, 60-, 90-day-old WT and SOD1G93A mice. Figure 3A shows that mGluR1
expression did not change significantly in SOD1G93A mice with respect to age-matched WT mice at any
age tested. Similar results were obtained with regard to mGluR5 expression (Figure 3B).
Figure 3. mGluR1 and mGluR5 expression in spinal cord synaptosomes from WT and SOD1G93A mice.
SOD1G93A mice were sacrificed at postnatal day 30, 60, and 90 days. Age-matched WT mice were used
as controls. (A) mGluR1 and (B) mGluR5 expression were measured by SDS 4–20% polyacrylamide gel
electrophoresis (PAGE) and western blot (WB) onto nitrocellulose membranes, using 20 µg of detergent
soluble protein extracts from the homogenate of spinal cord synaptosomes. Mouse monoclonal
antibodies anti-mGlu1 receptor, rabbit monoclonal antibody anti-mGluR5, and mouse monoclonal
antibody anti-β-tubulin III were used. Representative immunoreactive bands are shown. mGlu1 and
mGlu5 receptor expression levels were normalized for β-tubulin III in the same blotted membrane
and the quantization is reported in the bar plots. Results are expressed as the relative density and
the expression of mGluR1 or mGluR5 in WT synaptosomes is referred to as 1.00. Means ± SEM of
three independent experiments (three WT and three SOD1G93A mice) are presented. No significant
differences were detected (two-tailed student’s t-test).
Since total synaptosomal lysates may include heterogeneous populations of spinal cord synaptic
terminals differently expressing the two metabotropic receptors, we carried out immunofluorescence
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studies to investigate the levels of mGluR1 and GluR5 selectively expressed at glutamatergic axon
terminals during disease progression.
Confocal microscopy experiments were performed by staining spinal cord synaptosomes for the
vesicular Glu transporter 1 (vGluT1), to label glutamatergic axon terminals, and for mGluR1 or mGluR5
(Figure 4). Synaptosomal preparations efficiently stained for all the antibodies tested, thus allowing
the optimal analysis of the relative fluorescence intensity of mGluR1 or mGluR5 co-localizing with
vGluT1. The expression of vGluT1 did not vary between WT and SOD1G93A mice and this allowed its
use to calculate the relative intensity of mGluR1 or mGluR5 in glutamatergic synaptosomes. Figure 4A,
B shows that the relative intensity of mGluR1 and mGluR5 was not significantly modified at 30 and
60 days, although a trend toward an increase can be observed at the latter stage of the disease. On the
contrary, both mGluR1 and mGluR5 were significantly increased in SOD1G93A mice at 90 days of life
compared to WT mice (Figure 4C; mGluR1, p < 0.001, t(4) = −12.021; mGluR5, p < 0.001, t(4) = −12.728).
Figure 4. mGluR1 and mGluR5 expression in glutamatergic spinal cord synaptosomes from WT and
SOD1G93A mice.
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SOD1G93A mice were sacrificed at different stages of the disease: (A) 30 days of life, (B) 60 days of life,
and (C) 90 days of life, corresponding to pre-symptomatic (30 and 60 days) and early-symptomatic
(90 days) phases of the disease. Age-matched WT mice were used as controls. Spinal cord
synaptosomes were layered onto coverslips, fixed with paraformaldehyde, permeabilized with
triton X-100, and incubated with the specific primary and secondary antibodies, as described in
the Methods section. Samples were analyzed by laser confocal microscopy. The acquired images
show the triple-stained immune-positivity for Alexa Fluor 488-tagged anti-vGluT1 (blue; glutamatergic
synaptosomes), Alexa Fluor 647-tagged anti-mGluR1 (red), and Alexa Fluor 555-tagged anti-mGluR5
(green). The merge panels show the co-expression of vGluT1, mGluR1, and mGluR5. Bar plots
indicate the quantitative relative florescence intensity of mGluR1 or mGluR5 in vGluT1-positive spinal
cord synaptosomes. Representative images are shown (scale bar = 100 µm). mGluR1 and mGluR5
expression levels in vGluT1-positive synaptosomes were calculated. Means± SEM of three independent
experiments (three WT and three SOD1G93A mice) run in triplicate (three experimental replicates) are
presented. No significant differences were detectable in spinal cord glutamatergic synaptosomes from
30- and 60-day-old WT and SOD1G93A mice. On the contrary, the expression of mGluR1 and mGluR5
was significantly higher in synaptosomes purified from 90-day-old SOD1G93A mice. * p < 0.001 vs.
WT mice (two-tailed student’s t-test). (D) shows a magnification of the red frames in merge panels
(reported in Figure 4C) of spinal cord synaptosomes purified from 90-day-old WT and SOD1G93A mice.
Red arrows indicate axon terminals triple stained for vGluT1, mGluR1, and mGluR5 (scale bar = 3 µm).
Figure 4D report a magnification of the merge panels of Figure 4C (red frames), obtained
using spinal cord synaptosomes purified from 90-day-old WT and SOD1G93A mice and shows that a
large number of vGluT1-positive glutamatergic synaptosomes also co-express mGluR1 and mGluR5
(red arrows).
Therefore, mGluR1 and mGluR5 were over-expressed at glutamatergic axon terminals in 90-day-old
SOD1G93A mice.
2.4. Expression of mGluR1 and mGluR5 in Spinal Cord Total Tissue during Disease Progression
Group I mGluRs are present in neurons at the pre- and post-synaptic level, as well as in
non-neuronal cells, such as astrocytes, microglia and oligodendrocytes [41–43].
The data reported in the previous paragraph suggest that mGluR1 and mGluR5 expression does
not change significantly in the total synaptosomal population of SOD1G93A mice, being upregulated,
however, at the glutamatergic axon terminals. In order to ascertain whether these receptors are also
overexpressed in SOD1G93A mice at non-presynaptic sites (i.e., post-synaptically and/or in non-neuronal
cells), we conducted WB experiments on protein extracted from the whole spinal cord tissue of 30-,
60-, and 90-day-old WT and SOD1G93A mice. The results obtained overall show that group I mGluRs
are overexpressed during the progression of the pathology compared to WT mice, with mGluR1
expression significantly increased at 60 days (Figure 5A; p < 0.05, t(4) = −3.148) and mGluR5 expression
significantly augmented in SOD1G93A mice at 60 and 90 days of life (Figure 5B; p < 0.05, t(8) = −2.615
and p < 0.05, t(6) = −3.374, respectively).
These data suggest that mGluR1 and mGluR5 are overexpressed in the spinal cord of SOD1G93A
mice during disease progression even at early stages, and that this overexpression can be attributed
mainly to non-presynaptic structures.
Int. J. Mol. Sci. 2019, 20, 4552 9 of 19
Figure 5. mGluR1 and mGluR5 expression in spinal cord total tissue from WT and SOD1G93A mice.
SOD1G93A mice were sacrificed at postnatal day 30, 60, and 90. Age-matched WT mice were used as
controls. (A) mGluR1 and (B) mGluR5 expression were measured by SDS 4–20% PAGE and WB onto
nitrocellulose membranes, using 20 µg of detergent soluble protein extracts from the homogenate of the
whole spinal cord. Mouse monoclonal antibody anti-mGluR1, rabbit monoclonal antibody anti-mGluR5,
and mouse monoclonal antibody anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were
used. mGluR1 and mGluR5 expression levels were normalized for GAPDH in the same membrane.
Representative immunoreactive bands and quantization (bar plots) are shown. mGluR1 and mGluR5
levels are expressed as the relative density of SOD1G93A with respect to WT mouse bands, which
is referred to as 1.00. Bars report mean ± SEM of five independent experiments (five WT and five
SOD1G93A mice) run in triplicate (three experimental replicates) are presented. No significant differences
were detected in 30-day-old mice, while significant differences were found in 60- and 90-day-old mice.
* p < 0.05 vs. WT mice (two-tailed student’s t-test).
3. Discussion
Group I metabotropic glutamate receptors (mGluR1 and mGluR5) are actively involved in the
regulation of important cellular processes altered in ALS and play a key role in the complex ALS
scenario [44–50]. Starting from our previous results showing that mGluR1 and mGluR5 abnormally
increase the release of glutamate in the spinal cord of late symptomatic SOD1G93A mice [26], we
here investigated the expression and function of these receptors during disease progression to unveil
whether they can also modify glutamate transmission at more precocious stages of the disease.
Our functional results show that 3,5-DHPG induced Glu release in WT and SOD1G93A mice at 30,
60, and 90 days of life. Comparing the releasing effects observed in this work with previous results
in 120-day-old mice [26], it appears that the mGluR1/5 agonist exhibited the same efficacy (maximal
effect about 100% of potentiation at 30 µM), but lower potency, since the potentiation observed at
concentrations below 30 µM were always lower at 30, 60, and 90 days than at 120 days. In this work,
3,5-DHPG effects were comparable in WT and SOD1G93A mice at 30 and 60 days at any concentration
tested. On the contrary, 0.3 µM 3,5-DHPG was able to evoke a significant increase of Glu release
(approximately 25%) in 90-day-old SOD1G93A mice whereas it was ineffective in age-matched WT mice.
This difference may be consistent with that observed previously at 120 days since in that case, as in the
present experiments, the effects of 10 and 30 µM 3,5-DHPG were comparable in WT and SOD1G93A
mice and differences were observed at 1 µM and below, with 0.3 µM the highest concentration of
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3,5-DHPG producing Glu release in SOD1G93A, but not in WT mice. On the basis of the previous
results, we tested 0.03, 0.3, 3, and 30 µM 3,5-DHPG and, possibly due to the lower 3,5-DHPG potency
observed here, concentrations below 0.3 µM 3,5-DHPG were unable to disclose any further difference.
Alternatively, this may indicate that a sort of time-dependent iper-activation of mGluR1 and mGluR5
autoreceptors develops during the progression of the disease.
Our experiments with selective antagonists highlighted that both receptors are involved in the
Glu release potentiation seen at 90 days, since either the mGluR1 antagonist LY367385 or the mGluR5
antagonist MPEP virtually abolished the release of glutamate induced by 3,5-DHPG, suggesting the
existence of a functional interplay between the two receptors, as already proposed in late-symptomatic
SOD1G93A mice [26]. The data from confocal microscopy experiments, indicating the coexistence
of mGluR1 and mGluR5 on the same vGluT1-positive synaptosomes, support the results of release
experiments. Interestingly, mGlu1 and mGlu5 receptor–receptor interaction has been proposed after
measuring Glu release in mouse cerebral cortex synaptosomes by the same experimental set-up used
here [51], and the existence of mGluR heterodimers, including mGluR1/mGluR5, has been directly
demonstrated in different cell lines [52]. Thus, functional heterodimers might exist also in spinal
cord synaptosomes and we would attempt to speculate that the different expression of mGluR1
and mGluR5 in 90-day-old SOD1G93A mice could lead to the assembly of active heterodimers with
different stoichiometry, supporting a modified function, and thus explaining why 3,5-DHPG was able
to stimulate Glu release with a high affinity in SOD1G93A mice only.
The excessive 3,5-DHPG-induced Glu release was of vesicular origin, being abolished
by bafilomycin A1, which depletes the vesicle protonic gradient, hampering the storing of
neurotransmitters [40]. Additionally, it is exocytotic in nature since it was triggered by an increase of
[Ca2+]C and reduced by cytosolic Ca2+ buffering by BAPTA-AM, suggesting that Ca2+ originates by
intra-terminal stores. Moreover, the results obtained with the PLC inhibitor, U73122 [38], and the IP3
channel blocker, 2-APB [39], demonstrate that the effect of 3,5-DHPG on Glu release is mediated by
classical metabotropic receptors belonging to the group I mGluRs coupled to membrane phospholipid
hydrolysis, IP3 formation, and Ca2+ mobilization from the endoplasmic reticulum. We also found a
dysregulation of the synaptic Ca2+ homeostasis at the axon terminal level, characterized by resting
overload and increased levels also after 3,5-DHPG exposure. Whether 3,5-DHPG can augment by itself
the [Ca2+]C more efficiently in SOD1G93A mice is difficult to say on the basis of the present experiments,
and the extent of [Ca2+]C increase produced by the agonist would suggest that the basal level plays a
pivotal role. Whatever the case may be, the control of Ca2+ homeostasis is altered in SOD1G93A mice,
leading to increased [Ca2+]C. If we assume that a minimal threshold of [Ca2+]C is needed to trigger
Glu release, this condition would be more easily obtained in SOD1G93A mice that show a higher basal
level. Moreover, increased [Ca2+]C can activate various Ca2+-dependent signaling cascades involved
in presynaptic function and exocytosis processes, including the calpain-calpastatin protease system,
that indeed we found profoundly altered in SOD1G93 mice [53,54] and that could, in turn, also affect
release mechanisms [55].
Interestingly, abnormal exocytotic Glu release in the SOD1G93A mouse spinal cord does not seem
to be a unique characteristic of mGluRs since it was also observed using high KCl, ionomycin, or
hypertonic sucrose as releasing stimuli [25]. These stimuli exploit different mechanisms to produce
Ca2+-dependent and Ca2+-independent neurotransmitter release and it was determined that their
excessive effects are based on plastic changes of the Glu axon terminal biochemistry, leading to
increased phosphorylation of synapsin I and other key release-regulating proteins, increased number
of membrane-bound core complexes, and increased size of the readily releasable pool of vesicles [25,32].
It will be of interest to determine in future studies whether mGluR1 and mGluR5 adopt the same
mechanisms to produce the augmented Glu release in SOD1G93A mice. Furthermore, at variance
with the previously reported abnormal exocytotic release of Glu induced by depolarization of axon
terminals, which was detectable as early as at 30 days of life in SOD1G93A mice [32], the present
release modifications take place between 60 and 90 days. As a consequence, we can assume that the
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modification of the autoreceptor function at Glu synaptic terminals represents a consequence of disease
progression rather than a cause of the disease itself.
The release of glutamate was studied using purified synaptosomes stratified as a thin layer
on a support and up-down superfused with physiological medium in the presence or in the
absence of 3,5-DHPG and of the other tested substances. According to the characteristics of this
original technique [56,57], the mGluR1 and mGluR5 that modulate the release of Glu are localized
onto Glu-releasing axon terminals in the spinal cord. In line with these functional data, confocal
microscopy experiments in the mouse spinal cord revealed an increased expression of both mGluR1
and mGluR5 in vGluT1-stained (i.e., glutamatergic) synaptosomes obtained from early symptomatic
90-day-old SOD1G93A mice, when compared to WT mice. Differently, glutamatergic axon terminals
derived from the spinal cord of pre-symptomatic 30- or 60-day-old SOD1G93A mice proved only
a non-significant tendency to the increase of mGluR1 or mGluR5 expression, suggesting that the
abnormal activity of Glu release-regulating group I mGluRs parallels the development of disease
symptoms. Interestingly, no changes in the expression of the two receptors were detected in the spinal
cord synaptosomal homogenate prepared from 30-, 60-, and 90-day-old SOD1G93A mice, indicating
that the presynaptic overexpression of mGluR1 and mGluR5 preferentially or exclusively affects the
glutamatergic subpopulation of spinal cord axon terminals. At variance, an increase of mGluR1 and
mGluR5 expression was previously observed in WB experiments using synaptosomal homogenates
obtained from 120-day-old SOD1G93A [26], suggesting that, at this disease stage, the overexpression at
glutamatergic axon terminals is even more pronounced and/or that other synaptic terminals could
be involved.
Noteworthy, an overexpression of mGluR1 and mGluR5 was registered in the total spinal cord
tissue, but not in synaptosomes, between 30 and 60 days of life in SOD1G93A mice, suggesting that other
non-presynaptic receptors may play a role at earlier stages. As to the possible anatomical location of
these up-regulated non-presynaptic receptors, they might be located in spine and dendritic arborizations
at the postsynaptic level, where they modulate Glu transmission and multiple related events [58],
as well as in non-neuronal cells, such as astrocytes, microglia, and oligodendrocytes [59], which is
attractive in view of the well-known non-cell autonomous characteristics of the disease [16]. In fact,
it is now clear that astrocytes [17,60] and microglia [15,61] play a crucial role in MNs degeneration
during disease progression. Recent studies have shown that oligodendrocytes are also involved
in the non-cell autonomous nature of ALS [62,63]. Disclosing the role played by mGluR1 and
mGluR5 in the different non neuronal cell populations would be of crucial importance for a better
understanding of the neurodegenerative processes taking place in ALS and for the development of
effective pharmacological approaches.
The abnormal activity of mGluR1 and mGluR5 demonstrated previously [26] and in the present
work further support the rationale for the therapeutic exploitation of reducing mGluR1/5 activity.
Indeed, we demonstrated that the genetic reduction [64,65] or ablation [66] of mGluR1 or mGluR5
in SOD1G93A mice positively affects the disease course in SOD1G93A mice, prolonging survival,
ameliorating motor skills, and improving biochemical and cellular parameters that are altered during
the progression of ALS. These in vivo data are supported by previous in vitro evidence indicating
positive effects of group I mGluR activity inhibition on MNs degeneration [67–69]. The in vivo
beneficial effects of down regulating group I mGluR expression in ALS indicate that the amelioration
of the disease progression may additionally be due to down-regulation of receptors other than those
expressed on Glu-releasing axon terminals. The present demonstration that in total spinal cord tissue,
mGluR1 and mGluR5 are over expressed even earlier than those sited at Glu axon terminals supports
the above idea. Thus, the group I mGluRs genetic down regulation should create a virtuous cycle,
reducing both the number of receptors and their stimulation by released Glu.
To recapitulate, we demonstrated for the first time that the mGluR1- and mGluR5-releasing
function is altered in SOD1G93A mice starting from an early-symptomatic stage of the disease and that
these receptors are overexpressed in the spinal cord even at pre-symptomatic disease stages. This could
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have implication for ALS in vivo. It has been shown that chronic treatment with the prototypic mGluR5
antagonist MPEP attenuates cell death in vitro and delays the onset of motor symptoms and slightly
prolongs survival in vivo in SOD1G93A mice [49]. Selective and more potent mGluR5 antagonists, with
more favorable pharmacokinetics, are now available and have been tested in preclinical studies in
rodents [70–75] and in clinical trials in patients [76–78] for pathologies different from ALS, showing
a favorable safety profile and good efficacy. A positive outcome of in vivo pharmacological studies,
in ALS mouse models, with mGluR5 antagonists, already tested in patients, would pave the way to
rapid translational application to human ALS. Neuroprotective polytherapy with receptor antagonists
aimed at blocking both mGluR1 and mGluR5 could be even more efficacious.
In conclusion, group I mGluRs promise to be helpful druggable targets for pharmacological
interventions in ALS and further preclinical single- or multi-drug therapies in animal models of the
disease could obtain encouraging results, paving the way for clinical interventions in patients.
4. Materials and Methods
4.1. Animals
Adult B6SJL-TgN SOD1/G93A(þ)1Gur mice expressing a high copy number of mutant human
SOD1 with a Gly93Ala substitution [SOD1G93A] [30] were originally obtained from Jackson Laboratories
(Bar Harbor, ME, USA). They were bred at the animal facility of the Pharmacology and Toxicology
Unit of the Department of Pharmacy at the University of Genoa. Transgenic animals were crossed with
background-matched B6SJL wild-type female, and selective breeding maintained each transgene in
the hemizygous state. Non-transgenic littermates were used as controls (WT). Female and male mice
were used, and they were equally distributed in each series of experiments. Typization was performed
to analyze tissue extracts from tail tips (homogenized in phosphate-buffer saline, freeze/thawed
twice, and centrifuged at 23,000× g for 15 min at 4 ◦C) by staining for SOD1 after polyacrylamide
gel electrophoresis (10% resolving and 4% stacking) [49,79]. In SOD1G93A mice, death usually occurs
between 120 and 140 days. For experimental use, animals were killed at 30, 60, and 90 days of life,
corresponding to pre- (30 and 60 days) and early-symptomatic (90 days) stages of the disease. Animals
were housed at a constant temperature (22 ± 1 ◦C) and relative humidity (50%) with a regular 12:12 h
light cycle (light 7am and 7pm), throughout the experiments. Food and water were freely available.
All experiments were carried out in accordance with the guidelines established by the European
Communities Council (Directive 114 2010/63/EU of September 22nd, 2010) and with Italian D.L. n.
26/2014 and were approved by the local Ethical Committee and by the Italian Ministry of Health
(Project No. 75f11.2, Authorization No.97/2017-PR). All efforts were made to minimize animal suffering
and to use only the number of animals necessary to produce reliable results.
4.2. Synaptosomes Purification
Animals were euthanized and the whole spinal cord rapidly removed. Synaptosomes were
prepared essentially as described previously [80,81]. The tissue was homogenized in 15 volumes of
0.32 M sucrose, buffered at pH 7.4 with Tris-HCl, and using a glass-Teflon tissue grinder (clearance
0.25 mm). The homogenate was centrifuged (5 min, 1000× g at 4 ◦C) to remove nuclei and debris and
the supernatant was harvested and centrifuged at 12,000× g for 10 min. The pellet was suspended
in Tris-buffered 0.32 M sucrose and gently layered on a discontinuous Percoll® (Sigma-Aldrich,
St Louis, MO, USA) gradient (2%, 6%, 10%, and 20% v/v in Tris-buffered 0.32 M sucrose). After
centrifugation at 33,500× g for 5 min, the layer between 10% and 20% Percoll®, corresponding
to synaptosomal fraction, was collected and washed by centrifugation at 20,000× g for 15 min in
physiological medium, having the following compositions (mM): NaCl, 140; KCl, 3; MgSO4, 1.2;
NaH2PO4, 1.2; NaHCO3, 5; CaCl2, 1.2; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
10; glucose, 10; pH 7.4. The synaptosomal pellet was then resuspended in physiological medium for
cytosolic calcium concentration ([Ca2+]c) determination, release and confocal microscopy experiments,
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or in lysis buffer for Western blotting. Protein content was measured according to Bradford [82] using
bovine serum albumin (BSA; Sigma-Aldrich, St Louis, MO, USA) as standard. All the reagents were of
laboratory grade.
4.3. Release Experiments
Synaptosomes from 30-, 60-, and 90-day-old WT and SOD1G93A mice were incubated at 37 ◦C for 15
min in the presence of 0.1 µM [3H]d-Aspartate ([3H]d-Asp), a non-metabolizable analogue of glutamate
used to label the glutamate-releasing pools [83,84]. The synaptosomal suspension was equally
distributed on microporous filters placed at the bottom of a set of 24 superfusion chambers maintained
at 37 ◦C (Superfusion System, Ugo Basile, Comerio, Varese, Italy) [85,86]. Superfusion started with
standard medium at a rate of 0.5 mL/min and continued for 48 min. After 36 min of superfusion
to equilibrate the system, five 3-min samples were collected. (s)-3,5-Dihydroxyphenylglycine
(3,5-DHPG; 0.03–30 µM) was introduced at the end of the first sample collected (t = 39 min) and
maintained until the end of the experiment; the other drugs used were introduced at t = 30 min.
When appropriate, Ca2+ was omitted from t = 20 min. In some experiments, synaptosomes were
incubated for 30 min (15 min before and during [3H]d-Asp labelling) in the presence of 100 µM
1,2-bis-(2-aminophenoxy)-ethane-N,N,N0,N0-tetraacetic acid tetra acetoxymethyl ester (BAPTA-AM)
or with 0.1 µM bafilomycin A1. Collected samples and superfused synaptosomes were counted for
radioactivity. Tritium released in each sample was calculated as fractional rate × 100 (percentage of
the total synaptosomal neurotransmitter content at the beginning of the respective collection period).
Drug effects were evaluated by calculating the ratio between the efflux in the fourth sample collected,
in which the maximum effect of 3,5-DHPG was generally reached, and the efflux in the first sample
(basal efflux). This ratio was compared to the corresponding ratio obtained in appropriate controls that
were always run in parallel.
4.4. Confocal Microscopy
Purified synaptosomes (40 µg protein) from 30-, 60-, and 90-day-old WT and SOD1G93A mice were
stratified onto poly-l-lysine pre-treated coverslips and maintained for 45 min at room temperature to
allow setting and sticking to the surface. The preparations were fixed with 2% para-formaldehyde (15
min), washed with PBS (3 × 5), and permeabilized (5 min) with 0.05% triton X-100. After washing
(3 × 5) with PBS containing 0.5% BSA, the preparations were incubated overnight at 4 ◦C with the
primary antibodies diluted in PBS containing 3% BSA. The following antibodies were used: Guinea
pig anti-vesicular Glu transporter 1 (vGluT1, 1:1000, cat n. AB5905; Merk Millipore, Billerica, MA,
USA), mouse anti-mGluR1 (1:1000, cat n. 610964; BD Biosciences, NJ, USA), and rabbit anti-mGluR5
(1:500, cat n. ab53090; Abcam, Cambridge, UK). After washing (3 × 5) with PBS containing 0.5% BSA,
the preparations were incubated for 45 min with the secondary antibodies. The following antibodies
were used: Goat anti-guinea pig Alexa Fluor A488-conjugated (cat n. A11073), donkey anti-mouse
Alexa Fluor A647-conjugated (cat n. A31571), and goat anti-rabbit AlexaFluor A555-conjugated (cat
n. A21428) (Molecular Probes Europe, Leiden, The Netherlands). Antibodies were diluted 1:2000 in
PBS containing 3% albumin. Fluorescence image (512 × 512 × 8 bit) acquisition was performed by a
three-channel Leica TCS SP2 laser-scanning confocal microscope, equipped with 458, 476, 488, 514, 543,
and 633 nm excitation lines, through a plan-apochromatic oil immersion objective 63× (1.4 NA). Light
collection configuration was optimized according to the combination of chosen fluorochromes and
sequential channel acquisition was performed to avoid crosstalk. Leica “LAS AF” software package
was used for image acquisition. The estimation of co-localized proteins was performed by calculating
the co-localization coefficients [87].
4.5. Immunoblotting
Spinal cord synaptosomal or total tissue proteins from 30-, 60-, and 90-day-old WT and SOD1G93A
mice were separated by means of SDS-polyacrylamide gel electrophoresis; 4% to 20% gradient gels
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were used. The concentration of proteins in each sample fell in the linear portion of the standard curve.
Proteins were transferred to nitrocellulose membranes and electroblotted proteins were monitored
using Naphthol blue black staining (Sigma Aldrich, MO, USA). Membranes were saturated in 5%
skimmed-milk solution and incubated with the following antibodies: Mouse monoclonal anti-mGluR1
(1:500, cat n. 610964; BD Biosciences, San Jose, CA, USA); rabbit monoclonal anti-mGluR5 (1:500, cat n.
ab53090; Abcam, Cambridge, UK); mouse monoclonal anti-glyceraldeide phosphate dehydrogenase,
GAPDH (1:10000, cat. N. G8795; Sigma Aldrich, MO, USA); mouse monoclonal anti-β-tubulin
III (1:1000; cat. N. T8578; Sigma-Aldrich, MO, USA). After incubation with peroxidase-coupled
secondary antibodies, protein bands were detected and analyzed for optical density using an enhanced
chemiluminescence substrate (ECL, LiteAblot PLUS, Euroclone, Milan, Italy) and a chemiluminescence
system (Alliance 6.7 WL 20M, UVITEC, Cambridge, UK), and UV1D software (UVITEC). Bands of
interest were normalized for β-tubulin III or GAPDH levels in the same membrane.
4.6. Cytosolic Ca2+ Concentration
[Ca2+]C was determined in spinal cord synaptosomes from 30-, 60-, and 90-day-old WT and
SOD1G93A mice using the fluorescent dye fura 2-AM [79]. Synaptosomes were incubated for 40 min at
37 ◦C in physiological medium, in the presence of 20 mM CaCl2 and 5 mM fura 2-AM dissolved in
0.5% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA). Synaptosomes incubated in the
presence of 0.5% DMSO only were used to measure auto-fluorescence. Extra-synaptosomal fura 2-AM
was removed by centrifugation; pellets were re-suspended in ice-cold Ca2+-free physiological medium,
divided into 200-µL aliquots (200 µg protein/sample), and stored on ice until use. All measurements
were obtained within 2 h. Synaptosomes were diluted in a final volume of 2 mL of physiological
medium containing 1.2 mM CaCl2 and equilibrated at 37 ◦C for 15 min. The measurements were made
at 37 ◦C under continuous stirring using an RF-5301PC dual wavelength spectrofluorophotometer
(Shimadzu Corporation, Milan, Italy) by alternating the excitation wavelengths of 340 and 380 nm.
Fluorescent emission was monitored at 510 nm. Basal fluorescence was recorded for 1 min, then
synaptosomes were exposed to 3,5-DHPG (0.3 or 30 µM) for an additional 8 min. Calibration of the
fluorescent signals was performed at the end of each measurement by adding 10 mM ionomycin
in the presence of CaCl2 to obtain Fmax, followed by 10 mM EDTA (pH 8.0, buffered with 3 mM
Tris) to obtain Fmin. After correcting for extracellular dye, [Ca2+]C was calculated by the equation of
Grynkiewicz et al. [88], using a KD of 224 nM for the Ca2+-fura 2-AM complex.
4.7. Statistics
Data are expressed as mean ± SEM. The Shapiro–Wilk normality test was performed to assess the
normality of the data. Grubbs’ test for outliers was performed. Statistical comparison between two
means was performed by two-tailed student’s t-test while multiple comparisons were performed by
using the analysis of variance (one or two-way ANOVA, as appropriate), followed by the Bonferroni’s
post hoc test or Dunnet’s test, and p-values lower than 0.05 were considered significant. Analyses were
carried out using the SigmaStat software (Systat Software 3.5, Inc., San Jose, CA, USA).
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